Format

Send to

Choose Destination
Asian J Androl. 2014 Mar-Apr;16(2):274-9. doi: 10.4103/1008-682X.123664.

Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.

Author information

1
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Abstract

The development of human benign or malignant prostatic diseases is closely associated with androgens, primarily testosterone (T) and dihydrotestosterone (DHT). T is converted to DHT by 5-alpha reductase (5-AR) isozymes. Differential expression of 5-AR isozymes is observed in both human benign and malignant prostatic tissues. 5-AR inhibitors (5-ARI) are commonly used for the treatment of benign prostatic hyperplasia (BPH) and were once promoted as chemopreventive agents for prostate cancer (PCa). This review discusses the role of the differential expression of 5-AR in the normal development of the human prostate and in the pathogenesis and progression of BPH and PCa.

PMID:
24457841
PMCID:
PMC3955340
DOI:
10.4103/1008-682X.123664
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center